Medicare GLP-1 Bridge: 81 Days Until $50/Month Wegovy and Zepbound (April 2026 Countdown)

Verified April 27, 2026 (was: April 11, 2026): The Medicare GLP-1 Bridge launches July 1, 2026 and runs through December 31, 2027. Per the CMS Bridge documentation, the program covers FOUR drugs at a flat $50/month copay for eligible Medicare Part D beneficiaries: Foundayo (orforglipron oral), Wegovy injection (semaglutide), Wegovy oral tablet (semaglutide), and Zepbound KwikPen (tirzepatide). Approximately 3.4 million Medicare beneficiaries are expected to qualify. The $50 does NOT count toward the Part D deductible or the $2,100 annual out-of-pocket cap. If you're Medicare-eligible and have been waiting, now is the time to prepare — here's the 5-step checklist. For the comprehensive enrollment workflow, see our Medicare GLP-1 Bridge Enrollment Guide.

Quick answer: use our free Medicare GLP-1 Eligibility Checker to see if you qualify in 60 seconds. Then follow the prep steps below to be ready on launch day.

The 5-Step Prep Checklist (Before July 1, 2026)

Here's what to do in the 81 days between now and July 1 to ensure you can get your first Bridge-covered prescription on launch day:

• •Step 1: Verify your Medicare Part D enrollment. Call 1-800-MEDICARE or log into medicare.gov. The Bridge program runs through Part D, so enrollment is mandatory. If you have Medicare Advantage, check whether your plan includes drug coverage (MAPD) — if not, you may need to enroll in a standalone PDP during open enrollment (October 15 - December 7, 2026) to access the program after the first six months.
• •Step 2: Schedule a baseline medical visit. Your prescriber needs to document your BMI and any weight-related comorbidities (type 2 diabetes, hypertension, cardiovascular disease, sleep apnea, NAFLD, osteoarthritis). This documentation is what supports the prior authorization when the program launches.
• •Step 3: Ask your doctor about prior authorization. The Bridge program uses standard Part D prior auth workflow. Your doctor's office should already be familiar with this — but ask them to flag your chart for the July 1 launch so you're not caught in a backlog.
• •Step 4: Research your preferred medication. Four drugs are covered: Wegovy injection (semaglutide, 14.9% loss per STEP-1), Wegovy oral tablet (semaglutide 25mg, 16.6% loss per OASIS-4, requires fasting), Zepbound KwikPen (tirzepatide, 20.9% loss per SURMOUNT-1), and Foundayo (orforglipron, 12.4% loss per ATTAIN-1, no fasting required). All four at $50/month — see our Wegovy vs Zepbound and Foundayo vs Wegovy Pill head-to-head comparisons.
• •Step 5: Have a plan B ready. If prior auth is delayed or denied, know your backup. NovoCare Wegovy $349/mo and LillyDirect Zepbound $299/mo are cash-pay options that bypass insurance entirely. A telehealth brand alternative is Hers Wegovy $149/mo via the 2026 Novo partnership (cheapest brand Wegovy on the market) — or Sprout Health $250/mo for both brand and compounded routes with a dedicated care coordinator.

Who Qualifies: The Clinical Criteria

The Medicare GLP-1 Bridge uses the same clinical criteria as commercial Wegovy and Zepbound prescribing:

• •Medicare Part D enrolled (Original Medicare + standalone PDP, or Medicare Advantage with MAPD)
• •Age 65+ OR under 65 with disability (SSDI 24+ months) or End-Stage Renal Disease
• •BMI 30 or higher (obesity), OR
• •BMI 27 or higher with at least one weight-related comorbidity: type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea, non-alcoholic fatty liver disease, chronic kidney disease, or obesity-related joint problems
• •No contraindications to semaglutide or tirzepatide (medullary thyroid cancer history, MEN 2, severe GI disease, pregnancy)

Not sure if you qualify? Our free Medicare GLP-1 Eligibility Checker walks through all five criteria in 60 seconds and gives you a personalized result plus next steps.

What Happens After December 31, 2027

Correction (April 27, 2026): earlier reporting suggested the Bridge ended December 2026 with BALANCE taking over in 2027. Per the official CMS Bridge documentation, the Bridge is part of the BALANCE Model — not a precursor to it — and runs July 1, 2026 through December 31, 2027 (an 18-month demonstration window). The unresolved question is what happens January 1, 2028. Three scenarios:

• •Bridge phase (July 1, 2026 – December 31, 2027): $50/month flat copay, centralized CMS prior authorization, does NOT count toward Part D deductible or $2,100 OOPC cap
• •Permanent BALANCE Model coverage (most likely): CMS uses Bridge data to make GLP-1 weight-loss coverage a permanent CMMI Innovation Center model with continued Part D access. This is the path CMS appears to be planning toward
• •Congressional action: Congress passes legislation removing the 2003 Part D weight-loss-drug exclusion, making coverage statutory. The Treat and Reduce Obesity Act has been re-introduced in multiple sessions; passage timing uncertain
• •Coverage lapses (worst case): If neither happens, weight-loss GLP-1 coverage under Medicare Part D ends December 31, 2027 and patients return to cash pay or manufacturer savings programs

The Most-Favored-Nation Deal: Why $245 Matters

The $50/month copay is only possible because of the December 2025 Most-Favored-Nation (MFN) deal between the Trump administration and both drug manufacturers. Under MFN, Novo Nordisk and Eli Lilly agreed to charge Medicare a net price of $245/month for both Wegovy and Zepbound — 75-80% below the retail list price of $1,349 (Wegovy) and $1,086 (Zepbound).

The math: $245/month net → you pay $50 → Medicare pays the remaining $195. CMS estimates the program will cost approximately $2.1 billion in the first six months, covering roughly 3.4 million beneficiaries at an average of 4 months of treatment per patient (accounting for titration periods where patients aren't yet on the therapeutic dose).

This is unprecedented — it's the first time Medicare has negotiated a single-drug discount of this magnitude outside of the IRA Part D negotiation process. Both manufacturers agreed because (a) 3.4 million new patients is massive volume and (b) the alternative was being excluded from Medicare coverage entirely.

What to Watch Next

• •May 2026: CMS is expected to publish the final Bridge program operational manual, including the exact prior authorization template and provider enrollment requirements
• •June 2026: Part D plans finalize their Bridge integration. Watch for announcements from major PBMs (CVS Caremark, Express Scripts, OptumRx, Humana)
• •June 15-30, 2026: Pre-launch enrollment window opens for prescribers ready to submit on day one
• •July 1, 2026: LAUNCH DAY. First prescriptions filled. Expect pharmacy stock shortages in the first 2-4 weeks as demand ramps
• •October 15 - December 7, 2026: Medicare Open Enrollment for plan-year 2027 — switch Part D plans if your current one isn't handling Bridge claims efficiently
• •October 15 - December 7, 2027: Final open enrollment under the Bridge. CMS expected to publish post-Bridge transition guidance during this window
• •December 31, 2027: Bridge program ENDS. Coverage reverts to whatever permanent framework is in place at that point

Sources